CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Hormone treatment firm Biote (BTMD) going public in $737m IPO

By Kevin Donovan

16:56, 14 December 2021

Biote hormone pills
The average Biote clinic generates $100,000 in annual profit - Photo: Biote

Biote Holdings is merging with blank-cheque firm Haymaker Acquisition in a $737m (£556.8m) transaction to take it public, the companies have announced.

Haymaker Acquisition stock rose 0.70% to $10.70 from $10 per share after the market open but fell to $9.91 per share by noon EDT (UTC-5). Haymaker Acquisition trades over the Nasdaq exchange under the ticker HYACU.

Irving, Texas-based Biote is a hormone pill manufacturing company offering a platform for clinics to optimise treatment of age-related hormone treatments. The transaction is expected to close in the first half of 2022. The combined entity will trade over the Nasdaq exchange under the ticker BTMD.

“Biote is committed to educating and empowering providers to effectively treat patients and help them understand the critical role that hormones play in healthy ageing,” said Biote CEO Terry Weber in a prepared release.

“We welcome Haymaker as partners and look forward to the role our status as a public company will play in increasing access to, and awareness of, our leading hormone therapy practice-building business,” she said.

“We welcome Haymaker as partners and look forward to the role our status as a public company will play in increasing access to, and awareness of, our leading hormone therapy practice-building business.” Biote CEO Terry Weber

Transaction structure

Upon closing, Biote will have $195m (£147.4m) in cash and a credit facility provided by Truist Securities. Jefferies and Truist Securities are acting as financial advisors for BioTe Holdings. Citigroup and William Blair are acting as financial advisors to Haymaker.

Cooley is acting as legal advisor to Biote. DLA Piper and Ellenoff Grossman and Schole are acting as legal advisors to Haymaker.

Gold

2,038.24 Price
-0.240% 1D Chg, %
Long position overnight fee -0.0196%
Short position overnight fee 0.0114%
Overnight fee time 22:00 (UTC)
Spread 0.50

XRP/USD

0.61 Price
-0.810% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

BTC/USD

37,806.50 Price
+0.030% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Oil - Crude

78.87 Price
+1.330% 1D Chg, %
Long position overnight fee -0.0163%
Short position overnight fee -0.0056%
Overnight fee time 22:00 (UTC)
Spread 0.030

Biote reported $116m in revenue for the full-year 2020, noted Weber in a conference call following the transaction’s announcement.

Age-related hormonal therapy

“Women experience a 67% reduction in oestradiol between the mid-forties and mid-fifties. Over 47 million women in the US are affected by menopausal symptoms, yet only 28% undergo treatment,” Weber said on the call.

“Men, on the other hand, experience a 44% reduction in testosterone between the ages of 30 and 74. This condition affects 40% of men over 45, yet only 10 to 12% are receiving testosterone therapy.”

Biote manufactures soy and yam-based oestradiol and testosterone pellets, which it sells to doctors and clinics. Biote therapy is not covered by insurance and costs roughly $4 per day for women and $4.50 per day for men. The majority of Biote patients are between the ages of 45 and 56.

Biote currently has 4,700 client practitioners in 2,800 clinics in the United States. The average Biote clinic generates $100,000 in annual profit, Weber added on the call, with the top 100 of the 2,800 partner clinics reporting nearly $500,000 in annual profit.

Read more: Rigetti Computing goes public with SPAC merger

Related topics

Rate this article

The difference between trading assets and CFDs
The main difference between CFD trading and trading assets, such as commodities and stocks, is that you don’t own the underlying asset when you trade on a CFD.
You can still benefit if the market moves in your favour, or make a loss if it moves against you. However, with traditional trading you enter a contract to exchange the legal ownership of the individual shares or the commodities for money, and you own this until you sell it again.
CFDs are leveraged products, which means that you only need to deposit a percentage of the full value of the CFD trade in order to open a position. But with traditional trading, you buy the assets for the full amount. In the UK, there is no stamp duty on CFD trading, but there is when you buy stocks, for example.
CFDs attract overnight costs to hold the trades (unless you use 1-1 leverage), which makes them more suited to short-term trading opportunities. Stocks and commodities are more normally bought and held for longer. You might also pay a broker commission or fees when buying and selling assets direct and you’d need somewhere to store them safely.
Capital Com is an execution-only service provider. The material provided on this website is for information purposes only and should not be understood as an investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page then you do so entirely on your own risk.

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading